Regorafenib, a multitarget kinase inhibitor structurally sharing structural homology with sorafenib, exerts its therapeutic effects by targeting VEGFR, FGFR‐1, PDGFR, RAF, KIT, and RET, thereby inhibiting angiogenesis and modulating tumor microenvironment, which was approved by the US FDA in 2017 for HCC patients who have demonstrated refractoriness to sorafenib [529]. This evidence concerns the gene KDR and neoplasm.